Do you use immune checkpoint inhibitors in NSCLC patients with pre-existing, well-controlled autoimmune disease?
Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?
Answer from: Medical Oncologist at Academic Institution
While there is limited data on use of PD1 inhibitors in patients with pre-existing autoimmune conditions; in patients with metastatic NSCLC with limited options, it warrants consideration. This is obviously a high risk population to treat and close monitoring and co-ordinated care with specialist co...
Sign in or Register to read more